Abstract
Carbonic anhydrase (CA) activation was less investigated than CA inhibition, but in the last decades a detailed overview on the activation mechanism, classes of compounds possessing this profile, and many drug design studies led to significant progress in the field. As many CA isoforms are abundant in the brain, it has recently been demonstrated that their activation by drug-like compounds affords the possibility to design agents that enhance cognition, with potential therapeutic applications in aging, fear management, and neurodegenerative diseases in which the levels of CA activity are diminished. Furthermore, applications of CA activators in tissue engineering, such as artificial bone production, have also emerged, making this class of pharmacological agents of utmost interest.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
